Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma

The optimal sequencing of systemic treatments for metastatic urothelial cancer (mUC) is unknown. We assessed the efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1 to 3 inhibitor, in 67 patients with FGFR3-altered mUC by line of therapy. Objective response rates were 31% (early-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyou, Yung, Rosenberg, Jonathan E., Hoffman-Censits, Jean, Quinn, David I., Petrylak, Daniel, Galsky, Matthew, Vaishampayan, Ulka, De Giorgi, Ugo, Gupta, Sumati, Burris, Howard, Rearden, Jessica, Li, Ai, Xu, Cindy, Andresen, Corina, Moran, Susan, Daneshmand, Siamak, Bajorin, Dean, Pal, Sumanta K., Grivas, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460895/
https://www.ncbi.nlm.nih.gov/pubmed/34782263
http://dx.doi.org/10.1016/j.clgc.2021.10.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460895/
https://www.ncbi.nlm.nih.gov/pubmed/34782263
http://dx.doi.org/10.1016/j.clgc.2021.10.004

Ejemplares similares